Effects of torasemide combined with sacubitril/valsartan sodium table in patients with chronic heart failure
Zhang Chengwei
Huang Juan
Bi Songjie
Yin Rui
Li Xiaoping
Abstract：Objective To analyze the effects of torasemide combined with sacubitril/valsartan sodium table in patients with chronic heart failure(CHF).Methods A total of 147 CHF patients admitted to the Second Affiliated Hospital of Chengdu Medical College·Nuclear Industry 416 Hospital from January to December 2022 were selected,and they were divided into observation group(74 cases)and control group(73 cases)according to the random number table method.Both groups were given basic treatment,the control group was treated with sacubitril/valsartan sodium tablet,and the observation group was treated with torasemide on the basis of the control group.Both groups were treated for 2 months.The efficacy,ventricular remodeling indexes,plasma renin activity,angiotensin Ⅱ(Ang Ⅱ),serum N-terminal pro-brain natriuretic peptide(NT-proBNP),inflammatory factor levels,6 min walking distance(6MWD),quality of life before and after treatment and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group[93.2％(69/74)vs 82.2％(60/73),P=0.041].After treatment,the left ventricular mass index,interventricular septum thickness and left ventricular posterior wall thickness in the two groups were lower/smaller than those before treatment,and those in the observation group were lower/smaller than those in the control group(all P＜0.05).After treatment,the levels of plasma renin activity,Ang Ⅱ and serum NT-proBNP in both groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).After treatment,the levels of serum interleukin-6 and procalcitonin in both groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).After treatment,the 6MWD of the two groups was longer than that before treatment,and that of the observation group was longer than that of the control group,the score of Minnesota Cardiac Insufficiency Quality of Life Scale was lower than that before treatment,and that of the observation group was lower than that of the control group(all P＜0.05).No adverse reactions occurred in the two groups during treatment.Conclusions Torasemide combined with sacubitril/valsartan sodium table can improve the efficacy,inhibit ventricular remodeling,improve motor function and quality of life in patients with CHF.The mechanism may be related to the regulation of renin activity,the expression of Ang Ⅱ and NT-proBNP,and the reduction of inflammatory factors.
Keywords：Chronic heart failureTorasemideSacubitril/valsartan sodium tableVentricular remodelingRenin activityAngiotensin ⅡN-terminal pro-brain natriuretic peptide
Publication Date：2024-03-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 336-340 )